| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $76,571,672 | 37 | 100 |
| Kintz Samuel | PRESIDENT AND CEO | 0 | $0 | 1 | $272,739 | $-272,739 |
| Heyman Richard A. | director | 0 | $0 | 4 | $413,379 | $-413,379 |
| Garland J. Scott | director | 0 | $0 | 1 | $606,719 | $-606,719 |
| Kunkel Lori Anne | director | 0 | $0 | 2 | $850,255 | $-850,255 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | 0 | $0 | 5 | $1.46M | $-1.46M |
| Patel Anish | CHIEF OPERATING OFFICER | 0 | $0 | 3 | $1.61M | $-1.61M |
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 7 | $4.79M | $-4.79M |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | 0 | $0 | 11 | $5.33M | $-5.33M |
| Derynck Mika K | director | 0 | $0 | 1 | $9.56M | $-9.56M |
| ORBIMED ADVISORS LLC | 10 percent owner | 0 | $0 | 2 | $51.68M | $-51.68M |
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's …
Over the last 12 months, insiders at Enliven Therapeutics, Inc. have bought $0 and sold $76.57M worth of Enliven Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Enliven Therapeutics, Inc. have bought $0 and sold $43.88M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-19 | Sale | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 0.0082% | $38.48 | $231,546 | +12.89% | |
| 2026-10-19 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0068% | $38.47 | $192,342 | +12.89% | |
| 2026-10-01 | Sale | Garland J. Scott | director | 13,000 0.0198% | $46.67 | $606,719 | -10.15% | |
| 2026-08-17 | Sale | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 0.0089% | $58.58 | $352,551 | -22.39% | |
| 2026-08-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0074% | $58.59 | $292,931 | -22.39% | |
| 2026-08-04 | Sale | Derynck Mika K | director | 158,795 0.219% | $60.21 | $9.56M | -19.82% | |
| 2026-07-17 | Sale | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 0.0083% | $52.64 | $316,780 | -0.70% | |
| 2026-07-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0069% | $52.67 | $263,373 | -0.70% | |
| 2026-07-06 | Sale | Kunkel Lori Anne | director | 10,000 0.0141% | $50.49 | $504,903 | +4.34% | |
| 2026-06-22 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 860,123 1.2155% | $45.36 | $39.01M | +10.74% | |
| 2026-06-17 | Sale | Hohl Benjamin | CHIEF FINANCIAL OFFICER | 6,018 0.0096% | $43.80 | $263,577 | +13.39% | |
| 2026-06-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.008% | $43.80 | $219,017 | +13.39% | |
| 2026-06-15 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 281,408 0.4911% | $45.02 | $12.67M | +20.05% | |
| 2026-06-05 | Sale | Kunkel Lori Anne | director | 10,000 0.0163% | $34.54 | $345,351 | +45.48% | |
| 2026-05-18 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0082% | $39.79 | $198,971 | +23.95% | |
| 2026-04-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0083% | $47.67 | $238,352 | -4.16% | |
| 2026-03-25 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 40,000 0.0661% | $35.10 | $1.4M | +27.79% | |
| 2026-03-17 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 5,000 0.0084% | $27.76 | $138,800 | +62.41% | |
| 2026-03-10 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 10,129 0.0173% | $30.19 | $305,827 | +48.48% | |
| 2026-03-09 | Sale | Collins Helen Louise | CHIEF MEDICAL OFFICER | 29,871 0.0513% | $30.02 | $896,811 | +50.96% |
| Increased Positions | 66 | +40.74% | 8M | +13.17% |
| Decreased Positions | 74 | -45.68% | 5M | -8.28% |
| New Positions | 20 | New | 2M | New |
| Sold Out Positions | 27 | Sold Out | 3M | Sold Out |
| Total Postitions | 154 | -4.94% | 62M | +4.89% |
| Orbimed Advisors Llc | $123,691.00 | 13.49% | 7.96M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $110,788.00 | 12.08% | 7.13M | -430,705 | -5.7% | 2025-09-30 |
| Commodore Capital Lp | $72,926.00 | 7.95% | 4.69M | 0 | 0% | 2025-09-30 |
| Fairmount Funds Management Llc | $57,676.00 | 6.29% | 3.71M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $54,678.00 | 5.96% | 3.52M | +551,390 | +18.58% | 2025-09-30 |
| Vr Adviser, Llc | $50,137.00 | 5.47% | 3.23M | -800,000 | -19.87% | 2025-09-30 |
| Polar Capital Holdings Plc | $48,096.00 | 5.25% | 3.1M | +44,713 | +1.47% | 2025-09-30 |
| Vanguard Group Inc | $39,674.00 | 4.33% | 2.55M | +142,378 | +5.91% | 2025-09-30 |
| Janus Henderson Group Plc | $27,872.00 | 3.04% | 1.79M | +77,171 | +4.5% | 2025-09-30 |
| Novo Holdings A/S | $22,164.00 | 2.42% | 1.43M | +341,828 | +31.52% | 2025-09-30 |